CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Formoterol +1 moredrug
Likely dose
Formoterol 12mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01194479
NCT01194479N/ACompleted
CompareCT.gov

The Effect of the Beta 2 Agonist, Formoterol, on Recovery From Hypoglycemia

Yale University·interventional·Posted Sep 3, 2010·Updated Mar 29, 2016

In Brief

A clinical study evaluating Formoterol and Placebo for Type 1 Diabetes. Completed, enrolled 14 participants across 1 site.

Detailed Summary

Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). The aim of this study is to determine whether a formoterol inhaler can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 3, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.8 years ago

Interventions

Formoteroldrug

Formoterol inhaler, 12mcg capsules, 4 capsules for one administration

Placeboother

Participants in both arms received placebo on 1 of the 2 visits.